Clincosm LogoSign in Get a demo

relapsing remitting multiple sclerosis

Showing 1 - 25 of 111
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Remitting Multiple Sclerosis Trial (PIPE-307 Dose A, PIPE-307 Dose B, Placebo)

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • PIPE-307 Dose A
  • +2 more
  • (no location specified)
Oct 9, 2023

Bafiertam Treatment In Routine Clinical Practice

Enrolling by invitation
  • Relapsing Remitting Multiple Sclerosis
  • Monomethyl Fumarate
  • West Hollywood, California
  • +1 more
Aug 3, 2023

Integrated Digital Solutions in Medical Care of Multiple

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • MS Care Platform (icobrain ms and icompanion ms)
  • (no location specified)
Jul 10, 2023

Visual Processing Speed and Objective Analysis of Ocular

Enrolling by invitation
  • Multiple Sclerosis
  • +3 more
  • Eye tracking
  • +3 more
  • Valladolid, Spain
    IOBA - Universidad de Valladolid
Jan 20, 2023

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Birmingham, Saint Louis (Glycemic

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Glycemic load
  • +2 more
  • Birmingham, Alabama
  • +1 more
Jan 4, 2023

Relapsing Remitting Multiple Sclerosis Trial (monomethyl fumarate 190 mg, dimethyl fumarate 240 mg)

Completed
Has Results
  • Relapsing Remitting Multiple Sclerosis
  • monomethyl fumarate 190 mg
  • dimethyl fumarate 240 mg
  • (no location specified)
Dec 5, 2022

Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis Trial in United States (ANK-700, Placebo)

Recruiting
  • Multiple Sclerosis (MS)
  • Relapsing Remitting Multiple Sclerosis
  • Cullman, Alabama
  • +14 more
Dec 13, 2022

Upper Extremity Function in Multiple Sclerosis Advanced

Active, not recruiting
  • Multiple Sclerosis
  • +7 more
  • Tampa, Florida
    Carol and Frank Morsani Center for Advanced Healthcare
Nov 2, 2022

Lesion Load and Location in Relation to Cognition, Fatigue and

Completed
  • Relapsing Remitting Multiple Sclerosis
  • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
  • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
  • Assiut, Egypt
    Eman Khedr
Oct 27, 2022

Relapsing Remitting Multiple Sclerosis Trial in United States (Vitamin D3)

Completed
Has Results
  • Relapsing Remitting Multiple Sclerosis
  • Vitamin D3
  • Carmichael, California
  • +15 more
Sep 12, 2022

Implementation ofNovel Functional Eye-Tracking Biomarker for

Recruiting
  • Clinically Isolated Syndrome
  • Relapsing Remitting Multiple Sclerosis
  • Eye-tracking
  • Montréal, Quebec, Canada
    Montreal Neurological Institute and Hospital
Sep 2, 2022

Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ublituximab
  • Pasadena, California
  • +7 more
Aug 19, 2022

Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination Trial in Australia, Canada, United

Terminated
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Dallas, Texas
  • +6 more
Aug 10, 2022

Mechanistic Studies of Teriflunomide in RRMS

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Relapsing Remitting Multiple Sclerosis Trial in Glasgow (Clinical assessment)

Enrolling by invitation
  • Relapsing Remitting Multiple Sclerosis
  • Clinical assessment
  • Glasgow, United Kingdom
    Clinical Research Facility
Jul 20, 2022

Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)

Terminated
  • Relapsing Remitting Multiple Sclerosis
  • Pleneva TM BGC20-0134
  • Placebo
  • Gent, Belgium
  • +34 more
Jun 2, 2022

Relapsing Remitting Multiple Sclerosis Trial in Portland (3 mg Melatonin, 5 mg Melatonin)

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • 3 mg Melatonin
  • 5 mg Melatonin
  • Portland, Oregon
    Providence MS Center
May 5, 2022

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Glostrup, Copenhagen, Denmark
  • +11 more
May 3, 2022

Exercise on Contactin-1 and Contactin-2 Level in Persons With

Completed
  • Relapsing Remitting Multiple Sclerosis
    • Elazığ, Turkey
      Fırat university
    Apr 22, 2022

    Relapsing Remitting Multiple Sclerosis Trial in Saint Louis (Intermittent fasting)

    Completed
    • Relapsing Remitting Multiple Sclerosis
    • Intermittent fasting
    • Saint Louis, Missouri
      Washington University in St Louis
    Apr 25, 2022

    Tysabri in Early Relapsing Remitting Multiple Sclerosis

    Active, not recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Amadora, Portugal
    • +17 more
    Apr 12, 2022

    Relapsing Remitting Multiple Sclerosis Trial in Worldwide (alemtuzumab GZ402673)

    Completed
    Has Results
    • Relapsing Remitting Multiple Sclerosis
    • alemtuzumab GZ402673
    • Cullman, Alabama
    • +130 more
    Mar 21, 2022

    Relapsing Remitting Multiple Sclerosis Trial in Norway (Rituximab, Ocrelizumab)

    Recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Bergen, Norway
    • +10 more
    Mar 18, 2022

    Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Caen (Cognitive rehabilitation,

    Recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Secondary Progressive Multiple Sclerosis
    • Cognitive rehabilitation
    • Standard Psychological care
    • Caen, Calvados, France
      University Hospital of Caen
    Mar 8, 2022